Rare disease drugmaker Electra Therapeutics on Thursday banked $350 million in an initial public offering, becoming the 21st biotechnology company to price a new stock issuance in 2026. Electra plans to use the proceeds to continue developing an experimental drug for secondary hemophagocytic lymphohistiocytosis or “HLH,” a rare, sometimes life-threatening immune disorder with no approved treatments. That drug, called ipsoprubart, is in a registrational trial. Electra expects to complete enrollme

- FDA approval represents a monumental milestone for patients with MPS IIIA and validates Abeona’s foundational R&D and clinical development efforts - - Ultragenyx successfully brought a life-changing therapy across the finish line for MPS IIIA patients and families - Sept. 18, 2026 -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today congratulated Ultragenyx Pharmaceutical Inc., o

Sept. 18, 2026 -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that it has entered into a partnership with QIMA Life Sciences, a world leading preclinical dermatology CRO, to explore the potential of several of CDT’s assets in autoimmune skin diseases. CDT plans to leverage QIMA’s unique access to human skin from both healthy donors and patients. The use of patient tissue offers the most clinically relevant data possible, providing rapid translation to clinic and pro

September 17, 2026 – The NationalInstitute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division ofthe National Institutes of Health (NIH), has awarded SignaBlok, Inc., a biopharmaceutical company focused on developing novel peptide antagonists of cell receptors, a Phase I Small Business Innovation Research (SBIR) grant to develop a new therapeutic approach for inflammatory bowel disease (IBD). SignaBlok’s approach to IBD therapy targets TREM-1, a cell-surface receptor that has emer

It is intended for scientific, financial and investor media only. If approved, Jyseleca will be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks

Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement Combined company to focus on developing first-in-class next-generation medicines for cardioendocrine diseases Marea has multiple late-stage clinical product candidates: MAR001/005 for severe hypertriglyceridemia (sHTG) currently in Phase 2b and MAR002 for the treatment of acromegaly which is advancing to a Phase 2 study Concurrent financing of $225 million from leading life sciences inve

Sling Therapeutics has closed a $123-million series C round as it advances linsitinib into Phase III testing for thyroid eye disease (TED), putting the oral small-molecule IGF-1R inhibitor on track to challenge infusion-based therapies including Amgen's Tepezza (teprotumumab-trbw) and Viridian Therapeutics' Lumvoa (veligrotug-vvze). The financing, led by Forbion with participation from TPG Life Sciences Innovations and new investor Sectoral Asset Management, comes as Sling begins dosing patient

Protocol Submitted for IRB Review at a Leading Cancer Research Institution, Advancing the Study Toward Site Initiation Sept. 17, 2026 -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics, today announced that, following review and comments from the U.S. Food and Drug Administration (FDA), the Phase 2a protocol evaluating Ketamir-2 in chemotherapy-induced peripheral neuropathy (CIPN) has

Partnership combines manufacturing, development and clinical operations expertise to accelerate Investigator-Initiated Trials and clinical execution in China Aug. 16, 2026 -- ProBio, a leading global contract development and manufacturing organization (CDMO) focused on biologics and cell and gene therapies (CGT), today announced a strategic collaboration with Kun Tuo, an IQVIA company and leading clinical research organization (CRO) in China. The partnership aims to accelerate Investigator-Init

Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR) If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroids¹ Recommendation based on data showing Cosentyx doubled sustained remission rates and delivered steroid sparing effects vs placebo; safety was consistent with established Cosentyx profile² Despite being a common inflammatory rheumatic di